Outsourcing in Clinical Trials West Coast (OCT West)
Talk Clinical Technology & Innovation track
Maximizing asset valuation for biopharma
Tue, Feb 11, 2025 · 2:45–3:15 PM PST Hyatt Regency San Francisco Airport
About this session
- Biopharma has historically focused on achieving regulatory approval for value creation
- Asset valuations at the time of licensing or sale can be increased by expanding research plans to address non-regulatory stakeholders
- At the same time, new innovations in R&D productivity can lower the cost of trials while better managing risks of trial success
